Different effects of dopamine and Piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry  by Jardon, Blandine & Bonaventure, Nicole
Pergamon 
0042-6989(95)00022-4 
Vision Res. Vol. 35, No. 19, pp. 2665-2673, 1995 
Copyright © 1995 Elsevier Science Ltd 
Printed in Great Britain. All rights reserved 
0042-6989/95 $9.50 + 0.00 
Different Effects of Dopamine and Piribedil 
(a Dopamine D 2 Agonist) on Frog Monocular 
Optokinetic Nystagmus Asymmetry 
BLANDINE JARDON,* NICOLE BONAVENTURE* 
Received 1 August 1994; in revised form 16 January 1995 
Frog monocular optokinetic nystagmus (OKN) displays a directional asymmetry, reacting only to 
stimulations in the temporal-nasal (T-N) direction. The nasal-temporal (N-T) component is almost 
absent. The systemic or intrapretectal injection of Piribedil, a D 2 dopamine agonist, provokes the 
appearance of a N-T component suppressing the monocular OKN asymmetry. Conversely, dopamine 
or haloperidol (a dopamine antagonist, acting mainly on D2 receptors) have no effect upon the 
monocular OKN unidirectionality. The monocular OKN N-T component still appears after adminis- 
tration of Piribedil even if this injection is preceded by administration of haloperidol which blocks the 
dopaminergic I)2 receptors. Moreover administration of atropine (a cholinergic muscarinic antagonist) 
following that of Piribedil suppresses the N-T component; when injected before Piribedil, atropine 
prevents the appearance of the N-T component. These results suggest that in our experiments, 
Piribedil binds with muscarinic receptors. 
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Frog 
Frog monocular horizontal optokinetic nystagrnus 
(H-OKN) displays a di~rectional symmetry. Stimulation 
in the temporal-nasal (T-N) direction is the only 
efficient to evoke the reflex. The nasal-temporal (N-T) 
stimulation is not able to provoke any eye movements. 
In previous studies, an attempt o find a pharmaco- 
logical explanation far the mechanism underlying 
H-OKN asymmetry was done. It was shown that 
GABAergic, cholinergic and glutamatergic systems are 
involved in this function and that drugs affecting these 
systems intervene at retinal as well as central pretectal 
levels. 
When GABAergic and cholinergic nicotinic antagon- 
ists were injected into the viewing recorded eye, they 
provoked the abolition of the H-OKN elicited by visual 
stimulation of this eye (Bonaventure, Jardon, Wioland, 
Yiicel & Rudolf, 1988; Yficel, Jardon, Kim & Bonaven- 
ture, 1990). These results correlate with the modifi- 
cations of the spatial organization of the retinal input 
observed in the same experimental conditions (Bonaven- 
ture, Wioland & Jardon, 1986; Bonaventure, Jardon, 
Wioland & Rudolf, 1987; Ariel & Rosenberg, 1991). 
Moreover these drugs provoke the appearance of a 
N-T component, suppressing the H-OKN asymmetry 
*Laboratoire de Neurophysiologie et Biologic des Comportements, 
UPR 419 du CNRS, 5 Rue Blaise Pascal, 67084, Strasbourg Cedex, 
France [Fax 33 88 61 29 08]. 
when acting on pretectal structures, either by systemic 
administration or by microinjections directly into the 
pretectal nuclei (Yiicel et al., 1990; Jardon, Yiicel & 
Bonaventure, 1992; Jardon & Bonaventure, 1992). 
The involvement of ACh in the OKN origin was also 
demonstrated in other structures: microinjections of 
carbachol into the cerebellar flocculus has provoked the 
acceleration of the building up of the slow phase velocity 
OKN in the rabbit (Tan, Collewijn & Van der Steen, 
1992, 1993). It was also shown that GABAB could have 
an inhibitory effect on OKN: administration of baclofen 
could reduce the optokinetic gain when injected either 
intramuscularly or intracerebroventicularly in the rat 
(Niklasson, Tham, Larsby & Eriksson, 1994). 
On the opposite (Jardon & Bonaventure, 1995), it was 
shown that dopamine, when administered either by 
systemic or intrapretectal route was without apparent 
effect on frog visual monocular H-OKN asymmetry. The 
slow phase velocity gain of the T-N component was 
hardly modified compared to that of control; it was just 
slightly increased, especially at the lowest drum speeds, 
when the drug was injected directly into the pretectum. 
The fast phase frequency was slightly reduced. A stimu- 
lation in the N-T direction never induced an OKN. 
Conversely, Piribedil (Servier) a dopamine agonist 
which is commonly used in Parkinson disease (Rondot, 
Bathien & Ribadeau-Dumas, 1975; Truelle, Chanelet, 
Bastard, Six & Emile, 1979), provoked the appearance of
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a N-T component, suppressing the monocular OKN 
asymmetry. This was observed when Piribedil was 
injected into the open eye, the closed eye or directly into 
the pretectum. These conflicting results obtained with 
dopamine on the one hand and with Piribedil on the 
other hand are not easily understandable. Indeed, dopa- 
mine activates both D~ and D2 receptors ince Piribedil 
itself activates D2 receptors, its metabolite showing a 
large affinity for the D~ receptors. Then, Piribedil dis- 
plays a "dopamine like" profile with a direct action on 
receptors (Schmitt, Laubi6, Poignant, Krikorian, 
Evrard, Freyria & Arnaud, 1978). Moreover, in the 
striatum, tritiated-sulpiride which specifically binds with 
the D2 receptors, was displaced by dopamine as well as 
by the D 2 agonists: in this experimental condition 
Piribedil was more active than dopamine (Woodruff & 
Freedman 1982). In the rat brain Piribedil displaced the 
D2 antagonist, ritiated spiroperidol, whereas it had no 
effect on the specific D~ antagonist tritiated SCH 23390 
(G. Kato, cited by Evrard, 1991). 
These experiments well confirm that Piribedil can be 
considered as an agonist of dopamine, especially acting 
on the D2 receptors. 
In this framework, how can our apparent contradic- 
tory results be explained? Different hypotheses can be 
suggested, specifically Piribedil, which binds with the D 2 
dopamine receptors, could also bind with receptors 
which are not dopamine receptors. 
In order to demonstrate this hypothesis, we have 
studied the effects of Piribedil on H-OKN when the 
dopamine receptors were blocked. The strong neuro- 
leptic haloperidol, a non-specific dopamine antagonist 
was used for this purpose. The most probable candidates 
to account for the Piribedil effect on OKN are the 
cholinergic muscarinic binding sites. It was indeed 
shown (Kato cited by Evrard, 1991) that Piribedil can 
displace tritiated pirenzepine, a muscarinic M I ligand 
from its fixation sites. Even if this effect is relatively 
weak, it suggests that Piribedil could have a direct effect 
upon cholinergic muscarinic receptors. Nevertheless this 
weak affinity for the muscarinic receptor (ICs0 
3.6 x 10 -5 M) is in the range of the affinity of the "first 
generation" of ACh muscarinic ligands, i.e. muscarine 
and scopolamine. Like Piribedil, muscarine provoked 
the appearance of a N-T component at the same range 
of concentrations than those of Piribedil (Jardon & 
Bonaventure, 1992). Thus, we have also studied the 
effect of Piribedil on monocular H-OKN, when the 
cholinergic muscarinic receptors were blocked by 
atropine a muscarinic antagonist. 
In a first part of this work, the effects of an injection 
of haloperidol on the frog monocular OKN were studied 
and the effects of a subsequent administration of 
Piribedil at various concentrations following that of 
haloperidol were analysed. In a second part, we have 
studied, the effects of an injection of atropine at various 
concentrations, carried out before or after that of 
*It was previously shown (Jardon et al., 1992) that drugs injected into 
the closed eye are conveyed by the blood stream to central 
structures, as after systemic injections. 
Piribedil, knowing that atropine injected alone, does not 
modify the monocular H-OKN (Jardon & Bonaventure, 
1992). 
METHODS 
Monocular eye OKN was recorded in frogs (Rana 
esculenta) by the magnetic oil system in head restrained 
animals. The technique has been described in detail 
elsewhere (Jardon & Bonaventure, 1995). The frog was 
placed at the centre of the magnetic field in an opto- 
kinetic drum. The rotation speeds were constant and the 
drum was alternatively rotated clockwise and counter- 
clockwise to prevent habituation. The stimulation speeds 
were 1, 3, 6 and 9 deg/sec. 
The slow phase speed was measured from eye move- 
ment tracings using the cumulative curve of at least hree 
successive slow phases at steady state after elimination 
of the eye resetting fast phases. The velocity gain (the 
ratio of the slow phase speed to the stimulus speed) 
as well as the eye resetting fast phase frequency 
(beats/20 see) were analysed. 
The disappearance of the N-T component following 
the successive injection of Piribedil and atropine was 
admitted if the slow phase was no more measurable. Its 
appearance, following the successive injection of at- 
ropine and Piribedil was admitted when two successive 
slow phases separated by a fast phase were recorded. 
Two series of experiments were carried out. In the 
first, frogs received a first injection of haloperidol and a 
second of Piribedil when the effect of the first drug 
reached maximum. In the second one, frogs received an 
injection of Piribedil which was preceded or followed by 
an administration of atropine. Recordings were carried 
out before and after each drug administration; these 
drugs were administered either intravitreally, intraperi- 
toneally or directly into the pretectum contralateral to 
the open recorded eye. In the first case, 30/~1 of each 
solution were successively injected into the closed eye,* 
by a microsyringe under local anaesthesia; in the second 
one, 50 pl were injected into the abdomen of the frog. 
The technique of microinjection into the nucleus 
lentiformis mesencephali (nLM) of the pretectum has 
been previously described (Jardon & Bonaventure, 
1995). Each drug was successively administered in a 
volume of 0.2 pl over 20 sec. 
Haloperidol (Jansen) was diluted in saline. The 1 mM 
concentration used was determined from work realized 
in our laboratory on the chicken eye (Wioland, Rudolf 
& Bonaventure, 1990) and from pilot studies. Thus, 
11.3/~g were injected into the closed eye and 75 ng into 
the pretectum. 
Piribedil (Servier) was diluted in saline: concentrations 
used were 10, 1 and 0.1 mM when injected into the closed 
eye, and 0.1 mM only when injected into the pretectum. 
Thus, 118, 11.8 and 1.18 #g were respectively injected 
into the eye, and 7.8 ng into the pretecturn. 
Atropine sulphate (Sigma) diluted in PBS was used at 
50, 25, 10, 5 and 1 mM. 
For purposes of data analysis a Wilcoxon signed rank 
test was used. 
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RESULTS 
Control conditions 
The monocular H-OKN was systematically recorded 
in each animal before rejection at four different drum 
speeds and in both directions of stimulation. The frog's 
viewing eye followed the stripes moving in the T -N  
direction. When the stimulation was applied in the N-T  
direction, no eye movement could be detected irrespec- 
tive of the drum speed tested. Injection of the vehicle 
(saline) did not change the OKN when administered 
either into the eye (n = 3) [Fig. I(A)] or into the pretec- 
tum (n = 3) [Fig. 2(A)]. Surgical cannula implanted into 
the pretectum did not modify the control H-OKN. 
Monocular eye H-OKN recordings following adminis- 
tration of haloperidol into the occluded eye or the 
pretectum 
No spontaneous eye :movements were observed after 
haloperidol injection. 
After injection of haloperidol 1 mM (n = 18) into the 
occluded eye the recording OKN was slightly modified 
[Fig. I(B)]. The slow phase velocity gain of the T -N  
component was slightly but significantly reduced for the 
lowest drum speeds (1 deg P < 0.005; 3 deg P < 0.01) 
but not for the highest ones [Fig. 3(A, B, C)]. The 
resetting fast phase frequency was also significantly 
reduced for all drum speeds used. For instance, the fast 
phase frequency was reduced from 5.2 beats/20 sec be- 
fore injection, to 3.4 beats/20 sec following haloperidol 
for a stimulation speed of 6 deg/sec [Fig. 4(A, B, C)]. The 
stimulation in the N-T  direction remained unable to 
evoke the reflex and the slow phase velocity gain was still 
almost nil. 
After microinjection of haloperidol I mM (n = 6) 
[Fig. 2(B)] into the pretectum the slow phase velocity 
gain of the T-N component was not significantly 
modified compared to the control one, irrespective of the 
drum speed used [Fig. 3(D)]. 
The fast phase frequency was significantly (P < 0.005) 
reduced for all drum speeds except for a stimulation at 
6 deg/sec [Fig. 4(D)]. Thus, for instance, for a stimu- 
lation speed at 9deg/sec, the frequency was 7.7 
beats/20 sec before injection and was reduced to 5.8 
beats/20 sec after haloperidol. Stimulations in the N-T  
direction were insufficient o provoke the reflex. Spon- 
taneous recovery from the effects of haloperidol were not 
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FIGURE 1. Coil recordings of monocular eye OKN evoked by four constant drum speeds. (A) Before drug injection; 
(B) following intravitreal injection of haloperidol (1mM) into the closed, non-recorded eye; (C) following asubsequent i jection 
of Piribedil (1 mM) into the same ye. The speed and the direction of the stimulus are indicated on the left of the recordings. 
Calibration: vertical bar, angular displacement of 5 deg; horizontal bar, 10 sec duration. The OKN fast phase is upwards for 
a T-N stimulation, downwards for a N-T stimulation [in (C)]. 
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FIGURE 2. Coil recordings of monocular eye OKN evoked by four constant drum speeds. (A) Before drug injection; 
(B) following unilateral microinjection f haloperidol (1mM) into the nLM contralateral to the open, recorded eye. (C) 
Following a subsequent microinjection f Piribedil (0.1 mM) into the same pretectal nucleus. The speed and the direction of 
the stimulus are indicated on the left of the recordings. Calibration: vertical bar, angular displacement of 5 deg, horizontal 
bar, 10 sec duration. The OKN fast phase is upwards for a T-N stimulation, downwards for a N-T stimulation [in (C)]. 
Monocular eye H-OKN recordings following successive 
administration of haloperidol and Piribedil into the 
occluded eye or the pretectum 
When the effect of the drug was maximal, 30 min after 
administration of haloperidol (1 mM) into the occluded 
eye, an injection of Piribedil was achieved by the same 
route, at various concentrations (0.1 mM n = 6; 1 mM 
n = 5; 10 mM n = 4) [Fig. I(C)]. 
For a T -N  stimulation, no important change was 
noted in the monocular eye horizontal OKN when 
compared to that recorded following the first injection of 
haloperidol. The average velocity gain did not change 
significantly from previous values [Fig. 3(A, B, C)]. Only 
the strongest concentration of Piribedil (10 mM) had 
provoked an increase in the velocity gain at the lowest 
drum speeds (1 and 3 deg/sec) [Fig. 3(A)]. 
For the lowest concentration of Piribedil (0.1 mM) the 
resetting fast phase frequency was not significantly 
modified when compared to that of the OKN recorded 
after the first injection of haloperidol. It remained 
slowed down compared to that of the control [Fig. 4(C)]. 
On the other hand, the fast phase frequency increased 
at the two other concentrations reaching almost the 
values of the control (observed before haloperidol 
administration) [Fig. 4(A, B)]. 
For a N-T  stimulation, frogs displayed an eye 
H-OKN with slow phases following the stripe motion 
and resetting fast phases. This N-T  component did not 
exist in controls as well as in H-OKN recorded after 
haloperidol injection. The average velocity gain in- 
creased significantly for all drum speeds tested 
(P < 0.005). The difference between the velocity gain of 
the H-OKN evoked by a T -N  stimulation and that 
evoked by a N-T  stimulation was no longer significant 
after the injection of Piribedil, irrespective of the concen- 
tration used [Fig. 3(A, B, C)]. This was true also for the 
measure of the fast phase frequency (not shown). 
Piribedil (0.1 mM) was administered 10min after a 
microinjection of haloperidol (1 mM) into the pretectum 
by the same route [Fig. 2(C)]. 
The results are identical to those observed following 
successive administration of haloperidol and Piribedil 
into the eye [Fig. 3(D)]. For a stimulation in the T-N 
direction, the H-OKN was not modified, and the vel- 
ocity gain remained unchanged, irrespective of the drum 
speed used. In the same manner, the fast phase fre- 
quency was not modified compared to that of the 
H-OKN measured after haloperidol administration 
[Fig. 4(D)]. 
Stimulations in the N-T  direction provoked an 
H-OKN with slow phases and resetting fast phases. This 
H-OKN was totally similar (as far as gain and fast phase 
frequency are concerned) to that observed following 
T -N  stimulations. 
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FIGURE 3. Means values of slow phase velocity gain of monocular eye H-OKN before (C)), and following unilateral successive 
injections of haloperidol 1mM (0) and subsequent injection of Piribedil (&) into the occluded eye [(A) Piribedil 10 raM; 
(B) Piribedil I mM; (C) Piribedil 0.1 mM] or into the pretectum [(D) Piribedil 0.1 raM]. The OKN gain in response to T-N 
stimulations i drawn on the fight, the OKN gain in response to N-T stimulations i drawn on the left of the graph. The vertical 
bars indicate the SD. 
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F IGURE 4. Mean values of the fast phase frequency (beats/20 sec) of monocular eye H-OKN in response to a T -N  stimulation, 
before (©), and following unilateral successive injections of haloperidol 1 mM (0)  and Piribedil (A)  into the closed eye. 
[(A) Pir ibedi110 mM;  (B) Piribedil 1 mM;  (C) Piribedil 0.1 mM] or into the pretectum [(D) Piribedil 0.1 mM]. The vertical 
bars indicate the SD. 
Monocular H-OKN following successive intraperitoneal 
administration of Piribedil and atropine 
The intraperitoneal injection of 10 mM Piribedil pro- 
voked the appearance of the N-T  component. When the 
effect of Piribedil was maximal, 30 min after injection, 
atropine was injected by the same route. The concen- 
tration of Piribedil remained constant during all these 
experiments, while that of atropine has varied. 
For a T -N  stimulation, no change was observed in the 
monocular H-OKN, when compared to that recorded 
following the first injection of Piribedil, irrespective of 
the concentration of atropine. 
For a N-T  stimulation, the effect was related to the 
concentration of atropine injected: at the highest concen- 
trations (50 mM, n = 10; 25 mM, n = 3) the N-T  com- 
ponent always disappeared 40 min after injection, as 
soon as the inhibitory effect of atropine was efficient. The 
N-T  component reappeared no sooner than 2 hr later, 
when the effect of atropine had vanished. It was ob- 
served that, in seven animals, at a concentration of 
atropine 10mM (n = 16), the N-T  component never 
disappeared. It was still present 10-50 min in the OKN 
of nine other frogs, and then it disappeared uring about 
2 hr. 
A concentration of atropine 5mM (n = 13) did not 
suppress the N-T  component in the OKN of five frogs. 
Eight frogs have still reacted to the N-T  stimulation 
during periods of 25-75 min. Then the N T component 
disappeared during about 90 min and reappeared later, 
when the drug effect of atropine had vanished. All these 
results have been expressed in percentage of animals 
whose OKN N-T  component disappeared after succes- 
sive administration of Piribedil 10 mM and atropine at 
various concentrations (Fig. 5). 
Monocular H-OKN following simultaneous intraperi- 
toneal administration of atropine at various concentrations 
and of Piribedil (lOmM) 
The N-T  component did not appear when atropine 
50 mM (n = 4) or 25 mM (n = 3) and Piribedil (10 raM) 
were simultaneously injected and the OKN is remained 
asymmetrical. At a concentration of atropine 10mM 
100 • ,e 
8° 
60 
~a  4020 OI % N--T ;~sa-pP;P~irnanece 
I I 
0 10 20 30 40 50 
Atropine concentration (mM)  
F IGURE 5. Percentage of frog OKN in which the N-T  component 
observed after a first injection of Piribedil disappears as a function of 
the concentration of atropine injected afterwards (O). Percentage of 
frog OKN in which the N-T  component does not appear as a function 
of the concentration of atropine injected before Piribedil (0 ) .  
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(n = 13), nine frogs did not react to the N-T stimu- 
lation, while the four others displayed a symmetrical 
OKN, about 90 min after injection of both drugs. A 
concentration f atropine 5 mM (n - 14) prevented the 
N-T component to appear in the OKN of eight frogs. 
The N-T component was present in the OKN of the six 
other frogs, but it disappeared after 1 hr in three of 
them. For concentration of atropine 1 mM (n = 10), 
four animals have only displayed the T-N component, 
while the six others have always presented a symmetrical 
OKN. 
All these results were expressed in percentage of 
animals which have not displayed an OKN N-T 
component following simultaneous administration of 
atropine at various concentrations and of Piribedil 
10 mM (Fig. 5). 
DISCUSSION 
The horizontal frog OKN is asymmetrical in mon- 
ocular viewing conditions, the T-N stimulation being 
only efficient, the N-T one being unable to evoke 
the reflex as already observed (Birukov, 1937; Dieringer 
& Precht 1982; Bonaventure, Wioland & Bigenwald, 
1983). 
In a previous paper (Jardon & Bonaventure, 1995) 
we have demonstrated that dopamine does not modify 
this asymmetry and that the N-T component does not 
occur after administration of the drug. In the same 
manner, haloperidol, a non-specific dopamine antag- 
onist, does not intervene in the monocular OKN 
asymmetry and does not provoke the appearance of 
an OKN after a stimulation in the N-T direction. 
Like dopamine, haloperidol, has provoked only mild 
effects on monocular H-OKN: when injected systemi- 
cally, haloperidol has slightly reduced the slow phase 
velocity of the T-N component especially at the lowest 
drum speeds, while when injected into the pretectum 
it had no effect. Conversely, dopamine has provoked 
a little increase in the slow phase velocity when the 
drug was administrated directly into the pretectum. 
The fast phase frequency slightly decreased following 
dopamine injection, only at the highest drum speeds, 
while it decreased at all drum speeds tested after 
haloperidol. 
The absence or minimal effects of dopamine as well 
as those of haloperidol on monocular H-OKN indicate 
that dopaminergic mechanisms do not seem to be in- 
volved in the monocular H-OKN asymmetry. This 
lack of effect is observed when the drugs are admin- 
istered at retinal as at pretectal levels, though dopa- 
mine immunopositive cells and D~ and D2 binding 
sites are numerous in the retina (Ehinger, 1983; Elena, 
Denis, Kosina-Boix & Lapalus, 1989). In the mesen- 
cephalic structures responsible for OKN, it is not 
known whether dopaminergic cells or receptors are 
present. The only data obtained were in the nBOR of 
the pigeon (Britto, Hanaassaki, Keyser & Karten, 
1989) in which fibres and terminals were scarcely 
labelled with antibodies directed against tyrosine 
hydroxylase, the synthesizing enzyme of catechol- 
amine. Nevertheless it is unclear whether doparnine or 
noradrenaline was synthesized from this enzyme, 
When acting on D2 receptors and using a protein 
G as a second messenger, dopamine is considered as 
an inhibitor amine in the central nervous system of 
vertebrates (Sandoval, Massieu, Araiza & Fernandez, 
1989; Vallar & Meldolesi, 1989). It is then possible 
that it may play a role in the maintenance of inhi- 
bition upon the N-T component as GABA or ACh 
through nicotinic receptors (Yficel et al., 1990; 
Bonaventure et al., 1988; Jardon et al., 1992). But this 
inhibitory effect remains hypothetical since haloperi- 
dol, barely modifies the frog monocular OKN, the 
N-T component remaining absent after injection of 
this dopamine antagonist. 
Moreover, we were surprised to discover that 
Piribedil which is considered as a D2 dopamine ago- 
nist, and which is used as such in Parkinson disease, 
displayed characteristics other than those of dopamine 
in our experiments. 
Irrespective of the route of administration (systemic 
or intrapretectal) Piribedil provoked the appearance of
a N-T component suppressing the monocular OKN 
asymmetry. This observation is confirmed, even when 
the dopamine receptors have been blocked. Indeed, a 
previous administration of haloperidol which binds 
with the dopamine D~ and D2 receptors does not pre- 
vent the appearance of a N-T component of the mon- 
ocular H-OKN following a subsequent administration 
of Piribedil. This is the case irrespective of the concen- 
tration of Piribedil used (10, 1 or 0.1 mM) or the site 
of injection (occluded eye or pretectum). 
From the present experiment i can be concluded 
that Piribedil could act on receptors which are not 
dopaminergic receptors, these latter being blocked by 
haloperidol. In our experimental conditions Piribedil 
cannot displace haloperidol from its specific sites of 
fixation. It is suggested that haloperidol likely displays 
a higher affinity for the receptor than Piribedil, but it 
is also possible that the concentrations of Piribedil 
were too weak to displace haloperidol. However some 
observations realized by injecting lower concentrations 
of haloperidol (0.1 and 0.01 mM) compared to a 
higher one (10mM) showed no modifications of the 
effect of a subsequent administration f Piribedil. Thus 
it could occupy other sites than dopaminergic recep- 
tors in mesencephalic structures responsible for 
H-OKN. 
An. histoautoradiographic study comparing the 
fixation of tritiated haloperidol versus tritiated 
Piribedil will help us to resolve this question. In the 
rat brain also, Piribedil does not always interact with 
dopamine receptors: while if it binds with the dopa- 
mine receptors in the substantia nigra and the nucleus 
accumbens, it does not in the striatum (Hall, Jenner 
& Marsden, 1983). 
In the retina also, Piribedil is not able to displace 
haloperidol from its sites of fixation: according to 
Doly (personal communication) this suggests that 
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haloperidol  and Piribedil do not systematical ly occupy 
the same sites of  f ixation in the retina. It could also be 
thought that Pir ibedil  acts by increasing the blood flow; 
this hypothesis cannot be retained in so far as dopamine 
is also known to provoke the same effect. 
Thus, what neuroreceptors could be bound with 
Pir ibedil  to account for the disappearance of directional 
OKN asymmetry? 
It is proposed that the cholinergic muscarinic system 
could be involved in the effect of  Piribedil upon the 
monocular  OKN.  Certain symptoms of  Park inson dis- 
ease are due not only to the degenerat ion of  catechol- 
aminergic containing neurons, but also to that o f  
cholinergic neurons in the brainstem (Hirsch, Graybiel ,  
Duyckaerts  & Javoy-Agid,  1987). Dopamine and its 
agonists exert anticholinergic effect through dopamin-  
ergic receptors located on cholinergic neurons at the 
nigro-str iatal  level. But this antichol inergic effect is not 
direct; therefore it cannot explain our results. Piribedil 
displays structural chemical analogies with ACh; more- 
over it is able to displace [3H]Pirenzepine (a M~ ligand) 
from its binding sites (Kato,  cited by Evrard, 1991), 
showing then that it can bind with muscarinic receptors. 
Though this effect is relatively weak (IC50 3.6 x 10 -5 M) 
it suggests that in our experiments, Pir ibedil  may act like 
a muscarinic agonist. In a previous work, we have shown 
( Jardon & Bonaventure, 1992) that muscarine has pro-  
voked the appearance of  a N-T  component  in the 
monocular  frog OKN at the same range o f  concen- 
trations than those of  Piribedil. 
This hypothesis eems to be confirmed, since it was 
shown that an administrat ion of  atropine (a cholinergic 
muscarinic antagonist),  which by itself has no effect 
upon the monocular  H-OKN,  antagonizes the disin- 
hibitory effect of  Piribedil. Atropine suppresses the N-T  
component  when it is injected after Piribedil; it prevents 
its appearance when injected before Piribedil. 
This experiment supports the hypothesis of  a direct 
effect of  Piribedil on muscarinic receptors, but it does 
not constitute direct proof.  Indeed it cannot be excluded 
that atropine acts on a mechanism different from that on 
which Piribedil  acts, and the effect obtained could be the 
result o f  the action of  both antagonist ic mechanisms. 
Only an h istoautoradiographic  study on the frog mesen- 
cephalon using tr it iated Piribedil  and atropine will al low 
us to elucidate whether atropine and Piribedil bind with 
the same receptors. 
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